Market Cap 3.97M
Revenue (ttm) 170,000.00
Net Income (ttm) -17.32M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -10,188.24%
Debt to Equity Ratio 0.00
Volume 45,900
Avg Vol 103,994
Day's Range N/A - N/A
Shares Out 2.85M
Stochastic %K 36%
Beta 1.19
Analysts Sell
Price Target $15.00

Company Profile

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the...

Industry: Biotechnology
Sector: Healthcare
Phone: 352 448 7797
Fax: 352 480 4620
Address:
2117 SW Highway 484, Ocala, United States
ultimatebastos
ultimatebastos Dec. 5 at 12:46 PM
$AIM https://aimimmuno.com/aim-immunotech-to-participate-in-live-fireside-chat-on-virtual-investor-closing-bell-series/
0 · Reply
Rev2134
Rev2134 Dec. 5 at 2:37 AM
$AIM Anyone know where to find the recording of today’s Fireside chat? The email says it would be available 2 hours after the presentation but I can’t find it.
1 · Reply
S_Templar
S_Templar Dec. 5 at 12:12 AM
$AIM The way I understood the interview, they're going to need a partner to help finance phase 3 when we get to that point. I was very surprised to hear him refer to potential billions. Even if the partner that they find will eat into the prophets, if it's going to be in the billions, it shouldn't be a problem. I also think I understood that it might not be till the end of 2026 before we get to the third phase. I was driving during the interview and I'm not the most familiar person with the zoom, but did anybody notice if zoom provided a number for how many people were listening in? Thanks
1 · Reply
Teleboy
Teleboy Dec. 4 at 9:30 PM
$AIM So, in sum, Pancreatic Cancer trial report from Erasmus due at the end of this year, or early 2026. Recurrent Ovarian the other main positive. Merck and AstraZeneca collaborating with AIM on the trials (sponsoring). Not much new to those who have been following this, excepting the Erasmus report coming for Pancreatic. But, much more focused and all in one place.
1 · Reply
Teleboy
Teleboy Dec. 4 at 9:01 PM
$AIM If anyone wants to comment on today’s broadcast please do. I can’t but am curious to see what Tom has to say.
0 · Reply
Chessdoc
Chessdoc Dec. 4 at 4:29 PM
$AIM Does someone remember what kind of golden parachute he gets if/when exiting the company?
2 · Reply
Chessdoc
Chessdoc Dec. 4 at 4:14 PM
$AIM When is Bozo Tom out of office? 
0 · Reply
Jonou23
Jonou23 Dec. 4 at 3:26 PM
0 · Reply
Teleboy
Teleboy Dec. 4 at 12:33 PM
$AIM Dr Kalinski’s talk about one of the trials involving Ampligen (Rintatolimod), from a recent conference, just popped up on Youtube. If i have time i will cite the relevant clips later. https://m.youtube.com/watch?v=tzaUqLfwKXw
0 · Reply
TheLionofwallstreet
TheLionofwallstreet Dec. 4 at 1:44 AM
$CAPR $AIM could do this as well
1 · Reply
Latest News on AIM
Aimia Inc. (AIM:CA) Q3 2025 Earnings Call Transcript

Nov 12, 2025, 12:51 PM EST - 22 days ago

Aimia Inc. (AIM:CA) Q3 2025 Earnings Call Transcript


AIM ImmunoTech to Attend the 2025 Maxim Growth Summit

Oct 20, 2025, 9:15 AM EDT - 6 weeks ago

AIM ImmunoTech to Attend the 2025 Maxim Growth Summit


AIM ImmunoTech Announces Release of the Next CEO Corner Segment

Aug 21, 2025, 9:00 AM EDT - 3 months ago

AIM ImmunoTech Announces Release of the Next CEO Corner Segment


Why Is Micro-Cap AIM ImmunoTech Stock Surging?

Jul 28, 2025, 11:12 AM EDT - 4 months ago

Why Is Micro-Cap AIM ImmunoTech Stock Surging?


AIM ImmunoTech Resumes Trading on NYSE American

Jun 17, 2025, 8:55 AM EDT - 6 months ago

AIM ImmunoTech Resumes Trading on NYSE American


AIM ImmunoTech Announces 1-for-100 Reverse Stock Split

Jun 11, 2025, 4:15 PM EDT - 6 months ago

AIM ImmunoTech Announces 1-for-100 Reverse Stock Split


Aimia Inc. (AIMFF) Q1 2025 Earnings Call Transcript

May 13, 2025, 9:54 AM EDT - 7 months ago

Aimia Inc. (AIMFF) Q1 2025 Earnings Call Transcript


AIM ImmunoTech Inc. (AIM) Q4 2024 Earnings Call Transcript

Apr 1, 2025, 9:19 AM EDT - 8 months ago

AIM ImmunoTech Inc. (AIM) Q4 2024 Earnings Call Transcript


Aimia Inc. (AIMFF) Q4 2024 Earnings Call Transcript

Mar 28, 2025, 11:39 AM EDT - 8 months ago

Aimia Inc. (AIMFF) Q4 2024 Earnings Call Transcript


ultimatebastos
ultimatebastos Dec. 5 at 12:46 PM
$AIM https://aimimmuno.com/aim-immunotech-to-participate-in-live-fireside-chat-on-virtual-investor-closing-bell-series/
0 · Reply
Rev2134
Rev2134 Dec. 5 at 2:37 AM
$AIM Anyone know where to find the recording of today’s Fireside chat? The email says it would be available 2 hours after the presentation but I can’t find it.
1 · Reply
S_Templar
S_Templar Dec. 5 at 12:12 AM
$AIM The way I understood the interview, they're going to need a partner to help finance phase 3 when we get to that point. I was very surprised to hear him refer to potential billions. Even if the partner that they find will eat into the prophets, if it's going to be in the billions, it shouldn't be a problem. I also think I understood that it might not be till the end of 2026 before we get to the third phase. I was driving during the interview and I'm not the most familiar person with the zoom, but did anybody notice if zoom provided a number for how many people were listening in? Thanks
1 · Reply
Teleboy
Teleboy Dec. 4 at 9:30 PM
$AIM So, in sum, Pancreatic Cancer trial report from Erasmus due at the end of this year, or early 2026. Recurrent Ovarian the other main positive. Merck and AstraZeneca collaborating with AIM on the trials (sponsoring). Not much new to those who have been following this, excepting the Erasmus report coming for Pancreatic. But, much more focused and all in one place.
1 · Reply
Teleboy
Teleboy Dec. 4 at 9:01 PM
$AIM If anyone wants to comment on today’s broadcast please do. I can’t but am curious to see what Tom has to say.
0 · Reply
Chessdoc
Chessdoc Dec. 4 at 4:29 PM
$AIM Does someone remember what kind of golden parachute he gets if/when exiting the company?
2 · Reply
Chessdoc
Chessdoc Dec. 4 at 4:14 PM
$AIM When is Bozo Tom out of office? 
0 · Reply
Jonou23
Jonou23 Dec. 4 at 3:26 PM
0 · Reply
Teleboy
Teleboy Dec. 4 at 12:33 PM
$AIM Dr Kalinski’s talk about one of the trials involving Ampligen (Rintatolimod), from a recent conference, just popped up on Youtube. If i have time i will cite the relevant clips later. https://m.youtube.com/watch?v=tzaUqLfwKXw
0 · Reply
TheLionofwallstreet
TheLionofwallstreet Dec. 4 at 1:44 AM
$CAPR $AIM could do this as well
1 · Reply
DLTT4489
DLTT4489 Dec. 3 at 8:33 PM
$JAGX $CMMB $AIM why you looser care? 🤣🤣🤣
0 · Reply
jonjonson1234
jonjonson1234 Dec. 3 at 7:45 PM
$AIM The actual short interest in the company remains tiny, and is shrinking. Shares Outstanding 2.85M Float 2.75M % Held by Insiders 3.86% % Held by Institutions 4.93% Shares Short (11/14/2025) 6.91k Short Ratio (11/14/2025) 0.07 Short % of Float (11/14/2025) 0.25% Short % of Shares Outstanding (11/14/2025) 0.24% Shares Short (prior month 10/15/2025) 44.8k The company is dumping a lot of shares via its at-the-market share dumping scheme with Maxim, and the mechanics of how market makers introduce these new shares causes them to show on on Reg SHO data. So whenever they are dumping shares at-the-market, some of the willfully ignorant pumpers on this board will squawk about "naked shorts!" But, in reality, short interest in $AIM is very low.
1 · Reply
Zdxss1
Zdxss1 Dec. 3 at 7:38 PM
$JAGX $CMMB $AIM Why is this clown interested in the stock?
1 · Reply
rayk1
rayk1 Dec. 3 at 5:03 PM
$AIM 1 f****** Cent pre split!!!!! What a sad joke! Equels out!!! And please take the 90 year old (!!!) Mitchell from the BOD with you
0 · Reply
uuddlrlr
uuddlrlr Dec. 3 at 4:39 PM
$AIM AIM is at all time lows. On 8/15/2025 CEO Equels stated, "We remain encouraged by the growing body of positive clinical data demonstrated to date and believe that as we build momentum, we are well positioned to execute on a clear path toward government approval." If the leadership team is encouraged by progress then why are they not purchasing huge tranches of shares? Stock is down ~ 93% in the past year. This is massive "discount". Where are the insider purchases? Terminate the CEO & COO.
1 · Reply
kellermath
kellermath Dec. 3 at 1:28 PM
$AIM "SAVE THE DATE"
1 · Reply
rayk1
rayk1 Dec. 3 at 9:15 AM
$AIM yeah right,save the date🤮
0 · Reply
DLTT4489
DLTT4489 Dec. 2 at 9:45 PM
$JAGX get ready for another split like $CMMB $AIM
0 · Reply
yolotothemooon
yolotothemooon Dec. 2 at 8:07 PM
$AIM 🚀🌕 TO. THE. MOON. BITCH.
0 · Reply
rayk1
rayk1 Dec. 2 at 7:47 PM
$AIM 50 years of research in Ampligen…and nothing!!! Shareholders lost everything while this SCAM will go on and on… disgusting 🤮
2 · Reply
Aimforsuccess
Aimforsuccess Dec. 1 at 6:02 PM
$AIM Tommy getting ready to pump more like the last 10 years?
1 · Reply
MrTicker
MrTicker Dec. 1 at 1:55 PM
$AIM AIM ImmunoTech to Participate in Live ‘Fireside’ Chat on Virtual Investor Closing Bell SeriesLive video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Thursday, December 4th at 4:00 PM ET GLOBENEWSWIRE 7:55 AM ET 12/1/2025
0 · Reply